ALIM (Alimera Sciences, Inc.) חוב לטווח קצר להון

Alimera Sciences (ALIM) has developed an advanced sustained-release retinal drug delivery technology that replaces frequent injections with a single procedure lasting for years. However, the cost of these products is capped by insurance reimbursements, which limits the company's pricing power. Growth prospects are tied to the acquisition of Endo and the success of the drug Iluvien. The current metric stands at 0.04, and the price trajectory shown below on GURU.Markets illustrates the asset's price action.

For Alimera Sciences (ALIM), which is developing innovative retinal therapies, the history of the short-term debt-to-equity ratio reflects the balance between brand expansion and debt load. This metric compares liabilities with maturities of up to one year against equity, revealing liquidity risks during periods of market overheating, which allows an investor to timely detect a dangerous accumulation of debt and avoid purchasing the asset at its peak.